RCMNY
SWTX

Rubric Capital Management (New York)’s SpringWorks Therapeutics SWTX Stock Holding History

Rubric Capital Management (New York)’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-426,768
Closed -$21M – 74
2024
Q1 		$21M Buy
+426,768
New +$19.7M 0.62% 45

Other funds holding SWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Rubric Capital Management (New York)'s SWTX Position: Q2 2024 in Review

Rubric Capital Management (New York) sold out of SpringWorks Therapeutics (SWTX) in Q2 2024, closing a stake of 426,768 shares — an estimated $21M sold.

Rubric Capital Management (New York) first reported a position in SWTX in Q1 2024 and held it in 1 quarter. The position peaked at $21M in Q1 2024. 209 funds tracked by Wall St. Rank hold SWTX as of Q2 2024.

  • Rubric Capital Management (New York) reported no remaining SpringWorks Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Rubric Capital Management (New York) sold 426,768 SpringWorks Therapeutics shares in Q2 2024, an estimated $21M.
  • Rubric Capital Management (New York) first reported a position in SpringWorks Therapeutics in Q1 2024 and held it in 1 quarter.
  • Rubric Capital Management (New York)'s SpringWorks Therapeutics position peaked at $21M in Q1 2024.
  • 209 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2024.

Based on Rubric Capital Management (New York)'s 13F filing for Q2 2024, filed 13 Aug 2024.